• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Schizophrenia research and treatment >Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use
【24h】

Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use

机译：大麻素可用于治疗精神分裂症？大麻使用的不良和治疗作用的平衡神经化学框架

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent studies have found that cannabinoids may improve neuropsychological performance, ameliorate negative symptoms, and have antipsychotic properties for a subgroup of the schizophrenia population. These findings are in contrast to the longstanding history of adverse consequences of cannabis use, predominantly on the positive symptoms, and a balanced neurochemical basis for these opposing views is lacking. This paper details a review of the neurobiological substrates of schizophrenia and the neurochemical effects of cannabis use in the normal population, in both cortical (in particular prefrontal) and subcortical brain regions. The aim of this paper is to provide a holistic neurochemical framework in which to understand how cannabinoids may impair, or indeed, serve to ameliorate the positive and negative symptoms as well as cognitive impairment. Directions in which future research can proceed to resolve the discrepancies are briefly discussed.
机译：最近的研究发现，大麻素可改善精神分裂症人群的亚组神经心理功能，减轻其不良症状并具有抗精神病特性。这些发现与长期使用大麻造成的不良后果（主要是阳性症状）形成对照，并且缺乏针对这些相反观点的平衡的神经化学基础。本文详细介绍了精神分裂症的神经生物学底物以及大麻在皮质（尤其是额前）和皮质下大脑区域的正常人群中使用的神经化学作用。本文的目的是提供一个整体的神经化学框架，在其中了解大麻素如何损害或确实可以减轻正面和负面的症状以及认知障碍。简要讨论了今后的研究可以继续解决差异的方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号